Evidence map›Paper›PMID 40916553›Full record

ArticleBioanalysis2025

European Bioanalysis Forum recommendation on embracing a context-of-use-driven scientific validation for chromatographic assays in the light of ICH M10.

Philip Timmerman, Stuart McDougall, Neil Adcock, Cecilia Arfvidsson, Matthew Barfield, Stefan Blech, Kyra J Cowan, Luca Ferrari, Alessandro Greco, Michaela Golob and 10 more

Abstract read
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Philip TimmermanEuropean Bioanalysis Forum vzw, Brussels, Belgium.
Stuart McDougallArcinova, A Quotient Sciences Company, Bioanalytical Services, Alnwick, UK.
Neil AdcockPharmaron-UK, Metabolism, Rushden, UK.
Cecilia ArfvidssonAstraZeneca, Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, Gothenburg, Sweden.
Matthew BarfieldRoche Innovation Center Welwyn, Roche Pharma Research and Early Development, Hertfordshire, UK.
Stefan BlechBoehringer-Ingelheim Pharma GmbH & Co KG, Drug Metabolism and Pharmacokinetics, Biberach, Germany.
Kyra J CowanMerck KGaA, Research and Development, Drug Metabolism and Pharmacokinetics New Biological Entities, Darmstadt, Germany.
Luca FerrariRoche Pharma Research & Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Alessandro GrecoAptuit (Verona) Srl, an Evotec Company, ADMET & Bioanalytical Sciences, Verona, Italy.
Michaela GolobNuvisan GmbH, Bioanalysis, Neu-Ulm, Germany.
Lee GoodwinLabcorp, Bioanalytical Services, Harrogate, UK.
Richard HughesResolian Bioanalytics, Fordham, UK.
Tsvetelina IvanovaComac Medical, Quality and Compliance, Sofia, Bulgaria.
Anna LaurénBioanalysis, MinervaX, Lund, Sweden.
Robert NelsonBioAgilytix Laboratories, Hamburg, Germany.
Sonja NeitzelAxolabs GmbH, Bioanalytics, Kulmbach, Germany.
Tom VerhaegheJ&J Innovative Medicine, BDDS, Beerse, Belgium.
Nico van de MerbelICON, Bioanalytical Laboratories, Assen, the Netherlands.
Mike WrightGSK, Precision Medicine Biomarker & Bioanalytical Platforms, Stevenage, UK.
Stephen WhiteGSK, Precision Medicine Design Assurance, Stevenage, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use M10 guideline provides a global framework for bioanalytical method validation in studies intended for regulatory submission. While its structure ensures consistency and data reliability, the guideline also acknowledges that not all studies require the same level of validation. This paper examines where full compliance is essential and where scientific judgment allows for leaner, context-driven validation, such as in early-stage development, for additional matrices, metabolites, nonstandard biological matrices or studies intended for internal decision-making. Drawing on recent recommendations from the European Bioanalysis Forum, we introduce a decision-making flowchart and parameter table to support consistent application of a Context-of-Use approach to validation. These tools help guide when flexibility is appropriate while ensuring transparency and robustness in the data. The paper advocates continued dialogue both with end users of the data and the regulatory authorities to support a modernized, risk-based validation framework that remains aligned with patient needs and scientific integrity. We believe the recommendations in this paper are fully in alignment with the intent and core principles of ICH M10, while encouraging their application in a way that remains scientifically driven and proportionate to the purpose of the assay.

Indexed as

ChromatographyEuropeGuidelines as TopicHumansPharmaceutical PreparationsReproducibility of ResultsPharmaceutical Preparationsbioanalytical method validationchromatographic assayscontext-of-use (CoU)EBFICH M10study sample analysis

Identifiers

PMID40916553
PMCPMC12536768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.